The half-life, backwards

IGF-1 LR3 is a well-defined molecule with a poorly-defined human profile. This piece separates the two. It covers what the molecule is and how it behaves; it does not describe how to administer it, because there is no approved human dosing for any performance or body-composition use, and none is implied here.

Every claim below is tagged by evidence tier, so you can see exactly where a statement comes from – settled biochemistry, human clinical data, animal or cell-culture work, or community report. The tiers grade provenance, not confidence: a well-replicated rodent study is still preclinical.

Reference

Established biochemical, structural, or regulatory fact.

Clinical

Data from human trials or an approved drug label.

Preclinical

Animal or cell-culture data; no human equivalent published.

Community

Forum-reported and anecdotal — signal, not evidence.

IGF-1 LR3 is short for Long [Arg³] Insulin-like Growth Factor-1, and the full name is worth unpacking, because each half names a distinct modification. Native human IGF-1 is a 70-amino-acid single-chain protein of roughly 7,649 Da, folded and held together by three intramolecular disulfide bonds. LR3 makes two changes to it. Reference

• The “R3” (Arg³). Glutamic acid at position 3 is replaced by arginine. Position 3 sits inside the region that contacts the IGF-binding proteins, so swapping an acidic residue for a basic one disrupts that interaction — cutting IGFBP affinity by roughly 100-fold while preserving high-affinity binding to the IGF-1 receptor (IGF-1R).
• The “Long”. A 13-residue extension is added to the N-terminus (a sequence derived from methionyl porcine growth hormone). It is the half of the name that most write-ups forget.

The result is an 83-amino-acid protein of approximately 9,100 Da – commonly cited as ~9,111 Da, with some references giving ~9,117 Da depending on calculation method – with the native disulfide bridges preserved (manufacturer characterization; the analog was first described by Francis and colleagues at GroPep). Reference

That molecular weight is not trivia – it is the number every unit conversion depends on. Because LR3 is heavier than native IGF-1, a given mass corresponds to fewer moles, and any microgram-to-nanomole or reconstitution-concentration calculation has to use ~9,100 Da, not IGF-1’s ~7,649 Da. Our half-life & dosing calculator carries the correct molar mass for that arithmetic.

This is where most write-ups go wrong, so it is worth walking carefully. In the body, the overwhelming majority of IGF-1 – on the order of 97–99% – does not circulate freely. It is captured in a large ternary complex with IGFBP-3 and the acid-labile subunit (ALS). That complex is too big to leave the bloodstream easily, and it shields IGF-1 from degradation and clearance. This is why endogenous IGF-1 has a circulating half-life measured in hours – roughly 12–16 h – while the small free fraction clears in about 10–15 minutes (IGFBP biology). Reference

So binding to the IGFBPs is the primary half-life–extending mechanism for IGF-1. Hold that thought, because it is the crux.

LR3 was engineered specifically to evade the IGFBPs. Taken on its own, that should make LR3 behave more like free IGF-1 – which is to say it should shorten circulating persistence, not lengthen it. The frequent claim that reduced IGFBP binding “keeps more peptide free and therefore extends the half-life” has the causation reversed: being free is the fast-clearance state, not the slow one.

Whatever extended activity LR3 does show is better attributed to two things that are not a slower clearance: the N-terminal extension adds some resistance to proteases (against N-terminal aminopeptidases), and in the cell-culture assays most “duration” figures come from, simply evading the IGFBPs leaves more active peptide in play. Being unbound is not, by itself, a slow-clearance state. Preclinical

And the headline numbers deserve a hard flag. The widely repeated figures – a “20–30 hour half-life,” or the “56–72 hours” that appears on some reference pages – have no published human pharmacokinetic study behind them. They trace back to animal models and to how long the molecule stays bioactive in cell culture, then get repeated across vendor pages as if they were human PK. There is no human PK dataset for IGF-1 LR3. Community Preclinical

There are no controlled human trials of IGF-1 LR3. But that is a fact about LR3 specifically, not about IGF-1 as a class – and the distinction is the single most useful anchor available. Recombinant human IGF-1 (mecasermin) is FDA-approved and marketed as Increlex, for severe primary IGF-1 deficiency. It has a real label, real trials, and a documented adverse-event profile. LR3 is a modified analog of the same core molecule acting on the same receptor, so mecasermin’s label is the best-characterized window we have into what sustained IGF-1R agonism does in humans (Increlex prescribing information). Clinical

• Hypoglycemia. The most common and most immediate risk, given IGF-1's insulin-like activity. A reported acute-overdose case produced hypoglycemia that resolved with IV glucose.
• Tonsillar / lymphoid hypertrophy. Enlargement of the tonsils and adenoids.
• Soft-tissue and skeletal effects. Thickening of the soft tissues of the face is monitored during treatment; long-term overdosage is described as producing signs and symptoms of acromegaly. Intracranial hypertension and slipped capital femoral epiphysis are recognized in the pediatric IGF-1 literature.
• Systemic hypersensitivity. Including anaphylaxis, generalized urticaria, and angioedema — post-marketing anaphylaxis frequency estimated around 0.3% — plus local injection-site reactions.
• A malignancy contraindication. The label bars use in patients with active or suspected malignancy, or a history of it.

That last point deserves emphasis, because it connects directly to the concern most write-ups hand-wave.

Calling IGF-1’s cancer relationship “theoretical” understates it. There is a substantial body of prospective observational data linking higher circulating IGF-1 to cancer risk. A pooled individual-participant meta-analysis (up to ~10,554 cases) found IGF-1 positively associated with prostate cancer risk – an odds ratio around 1.29 for the highest versus lowest fifth of IGF-1 in prospective studies (Cancer Research, 2016) – and associations have been reported for breast and colorectal cancers as well (EPIC-Heidelberg, JCEM 2023). Clinical

A persistent idea is that injecting LR3 near a target muscle concentrates its effect there. The pharmacology argues against it: the IGFBP-evading design and systemic distribution mean LR3 acts as a whole-body growth signal, not a local one. Reference Preclinical

The compound usually invoked for genuinely local action is MGF (mechano growth factor) – but it is worth being precise about what MGF is and isn’t. MGF is not a “cousin”; it is a splice variant of the same IGF-1 gene (the IGF-1Ec isoform), whose distinguishing E-domain peptide is what people mean by “MGF.” And its evidence base is weaker, not stronger: the E-domain peptide’s receptor has not been definitively identified, and synthetic MGF is rapidly degraded in circulation. Pointing from a thin-evidence compound to a thinner-evidence one isn’t an upgrade. The full accelerator story – systemic IGF-1, the local pulse, and the analogs built to push it – is in the other pedal. Reference Community

• Not approved for any performance or body-composition use. IGF-1 LR3 is sold as a research chemical: unapproved for human use, which is different from unregulated. Distribution for human consumption is not lawful, and it is properly labeled for laboratory research use only.
• WADA-prohibited at all times. IGF-1 and its analogs fall under category S2 (peptide hormones, growth factors, related substances and mimetics) of the WADA Prohibited List — banned both in- and out-of-competition, with no off-season window. MGF is named in the same category. The 2026 Prohibited List took effect January 1, 2026.

Both points are settled regulatory fact (WADA Prohibited List). Reference

Because this is an unregulated-for-purpose research compound, purity and identity can’t be eyeballed – and for a folded, disulfide-bonded protein, the usual “99% by HPLC” line is necessary but not sufficient. The failure modes that matter here are specific, and they sit higher on the complexity ladder than a short synthetic peptide (where trust starts to mean something). Reference

• Intact mass by ESI-MS. Specifically to distinguish LR3 (~9,100 Da) from native IGF-1 (~7,649 Da) and from N-terminally truncated species. Substitution of a cheaper or truncated molecule is a real risk, and mass spec is what catches it.
• Correct disulfide folding. LR3 carries three disulfide bonds, and misfolded disulfide isomers are mass-identical to correctly folded material — mass spec alone won't distinguish them, and RP-HPLC may or may not resolve them depending on method. The only assay that actually confirms the molecule is folded and functional is a cell-based bioactivity assay.
• Endotoxin (LAL). For anything intended for injection in a research setting, bacterial endotoxin is arguably more consequential than the purity percentage — and it is routinely omitted from vendor COAs.
• Chain of custody. An accredited third-party lab, with a lot number on the COA that reconciles to the number on the vial.

Two cautions worth stating plainly. First, water and residual-solvent content is a legitimate line item but a distant priority next to identity, folding, and endotoxin – don’t let a tidy-looking moisture figure stand in for the assays that matter. Second, a vendor-supplied chromatogram is trivially fabricated; an unaccredited PDF with no reconcilable lot number is a marketing asset, not evidence. Provenance is the whole point – the same standard we apply across the methodology. Reference

IGF-1 LR3 is a well-defined molecule with a poorly-defined human profile. What’s solid is the biochemistry: an 83-residue, ~9,100 Da IGF-1 analog that evades the binding proteins and preserves IGF-1R activity. What’s not solid is almost everything downstream in humans – its true half-life, its dose-response, its long-term safety – none of which has been established in controlled human study.

The most reliable read on its likely effects comes from the approved IGF-1 product’s label and from the observational IGF-1/cancer literature, and both counsel caution rather than confidence. And the one correction to carry away is mechanical, not moral: evading the binding proteins does not, by itself, lengthen IGF-1’s half-life – it shortens it. Any longer-lasting activity is a matter of protease resistance and in-vitro availability, not slower bloodstream clearance, and the specific hour-figures quoted online are not human data.